Personalised Cancer Vaccination Strategies: Bridging Genomics, Bioinformatics, and Immunotherapy

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 15 | Issue : 03 | Page :
    By

    V. Basil Hans,

  • Swathi Bhat,

  1. Research Professor, Department of Management and Commerce, Srinivas University, Mangalore, Karnataka, India
  2. Assistant professor, Department of Commerce, St. Aloysius deemed to be university Mangalore, Karnataka, India

Abstract

Immunotherapy has revolutionized cancer treatment by harnessing the body’s immune system to detect and destroy cancer cells. Personalised cancer vaccines are one of the most promising options because they could allow treatment to be based on the specific tumour profile of each person. The goal of these vaccines is to make the immune system recognise and fight cancer-specific antigens, which will lead to strong and long-lasting anti-tumor responses. However, moving this method from preclinical models to clinical use is not easy. It involves finding the best tumor-associated antigens, improving vaccine delivery systems, and dealing with the fact that tumour immunogenicity is not the same in all cases. This study examines the present status of personalised cancer vaccine development, emphasising significant progress in antigen identification, delivery systems, and immune response assessment. We also look at clinical trials that have shown both the potential and the problems with this method, focussing on how personalised vaccines can be used with other cancer immunotherapy treatments such immune checkpoint inhibitors or adoptive T-cell therapy. We also talk about how finding biomarkers might help choose patients, how immune responses can vary, and how combination therapies are needed to make vaccines work better. As we move from the “bench” to the “bedside,” it becomes clear that personalised cancer vaccines, even though they are still in the early phases of clinical translation, might make a big difference in treatment results by giving patients more specific, targeted, and less harmful medicines. The path forward entails multidisciplinary collaboration, sustained innovation, and the enhancement of both technology and strategy, aiming to establish a new standard of care in oncology.

Keywords: Personalised Cancer Vaccines, Immunotherapy, Tumour Antigens, Antigen Discovery, Immune Checkpoint Inhibitors, and Clinical Translation.

[This article belongs to Research and Reviews : A Journal of Immunology ]

How to cite this article:
V. Basil Hans, Swathi Bhat. Personalised Cancer Vaccination Strategies: Bridging Genomics, Bioinformatics, and Immunotherapy. Research and Reviews : A Journal of Immunology. 2025; 15(03):-.
How to cite this URL:
V. Basil Hans, Swathi Bhat. Personalised Cancer Vaccination Strategies: Bridging Genomics, Bioinformatics, and Immunotherapy. Research and Reviews : A Journal of Immunology. 2025; 15(03):-. Available from: https://journals.stmjournals.com/rrjoi/article=2025/view=231739


References

  1. Pan RY, Chung WH, Chu MT, Chen SJ, et al. Recent advancements and clinical use of cancer vaccines: Targeting neoantigens. Cancer Sci. 2018;109(7):1979-1991. Available from: https://www.ncbi.nlm.nih.gov
  2. Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215-229. Available from: https://www.ncbi.nlm.nih.gov
  3. Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238-4246. Available from: https://www.ncbi.nlm.nih.gov
  4. Fan T, Zhang M, Yang J, Zhu Z, et al. Therapeutic cancer vaccines: Progress, challenges, and future opportunities. Cancer Commun (Lond). 2023;43(2):127-149. Available from: https://www.ncbi.nlm.nih.gov
  5. Mohsen MO, Vogel M, Riether C, Muller J, Salatino S, Ternette N, et al. Targeting mutated and germline epitopes confers preclinical efficacy of an instantaneously manufactured cancer nano-vaccine. Front Immunol. 2019 May 15;10:1015. doi:10.3389/fimmu.2019.01015. PMID:31156619; PMCID:PMC6532571.
  6. Cole G, McCaffrey J, Ali AA, McCarthy HO. DNA vaccination for prostate cancer: Key concepts and considerations. Cancer Lett. 2015;356(2 Pt B):191-199. Available from: https://www.ncbi.nlm.nih.gov
  7. Cappuccini F, Stribbling S, Pollock E, Hill AVS, et al. Immunogenicity and efficacy of a novel cancer vaccine using simian adenovirus and MVA vectors alone or with PD-1 blockade in a murine prostate cancer model. Cancer Immunol Immunother. 2016;65(6):701-713. Available from: https://www.ncbi.nlm.nih.gov
  8. National Cancer Institute. Using immunotherapy to fight cancer [Internet]. Bethesda (MD): National Cancer Institute; [cited 2025 Aug 30]. Available from: https://www.cancer.gov
  9. Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons, and beyond. Biomed Pharmacother. 2020 Apr;124:109821. doi:10.1016/j.biopha.2020.109821.
  10. Cleveland Clinic. Immunotherapy. Cleveland (OH): Cleveland Clinic; [cited 2025 Aug 30]. Available from: https://my.clevelandclinic.org
Regular Issue Subscription Review Article
Volume 15
Issue 03
Received 30/08/2025
Accepted 07/09/2025
Published 13/11/2025
Publication Time 75 Days
63

Login


My IP

PlumX Metrics